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Extracellular vesicles (EVs) are small-membrane vesicles secreted by most
cells types with the role to provide intercellular communication both locally
and systemically. The transfer of their content between cells, which includes
nucleic acids, proteins and lipids, confers the means for these interactions
and induces significant cellular behaviour changes in the receiving cell.
EVs are implicated in the regulation of numerous physiological and
pathological processes, including development and neurological and cardi-
ovascular diseases. Importantly, it has been shown that EV signalling is
essential in almost all the steps necessary for the progress of carcinomas,
from primary tumours to metastasis. In this review, we will focus on the
latest findings for EV biology in relation to cancer progression and the
tumour microenvironment.
This article is part of the discussion meeting issue ‘Extracellular vesicles
and the tumour microenvironment’.1. Introduction
Extracellular vesicles (EVs) are a means of intercellular communication between
neighbouring and distant cells. They contain nucleic acids, proteins and lipids,
which can direct the fate of the recipient cell. EVs have been described to have a
role in both physiological and pathological conditions and can modulate a
number of cellular processes such as proliferation, migration, invasiveness
and extracellular matrix (ECM) remodelling, generating a great interest in
many different biological contexts [1].
From the 1960s, a number of groups observed that vesicles secreted by
different cells in culture functional. While platelet-secreted vesicles regulated
blood coagulation [2], it was found that EVs could transport trophic substances
or nutrients to other cells [3]. Furthermore, different groups observed a role for
secretory vesicles in reticulocyte maturation through recycling of transferrin
and its receptor [4,5]. However, it was not until the late 1990s that a couple
of studies found that immune cell-derived EVs could act as antigen presenters
and T cell stimulators by expressing MHC class I and MHC class II molecules
on their surface [6,7]. These studies presented for the first time an unconven-
tional mechanism for intercellular communication, revealing the importance
of a role for EVs in the immune system. Nowadays, it is widely recognized
that EVs can have multiple functions in other physiological and pathological
scenarios such as in cancer and in cardiovascular and neurodegenerative
diseases [8].2. Extracellular vesicles: biogenesis
EVs are lipid bilayer vesicles secreted to the extracellular space by cells. Their
double membrane layer allows the EV content to be prevented from degra-
dation from exogenous nucleases and proteases, facilitating long-term and

















Figure 1. EV biogenesis and uptake. A simplified version of EV biogenesis is depicted on the left panel and EV uptake on the right. EVs can act locally, by affecting
the behaviour of nearby cells or systemically, by travelling via blood or the lymphoid system and influencing cells long-distance. On the left panel, the plasma
membrane of a cell can be endocytosed and trafficked to early endosomes and later to the multivesicular body (MVB). The MVB formed can either follow a
degradation pathway fusing with lysosomes (blue) or proceed to release exosomes (small circles with red dots) to the extracellular space by fusing with the
plasma membrane by exocytosis. On the other hand, microvesicles (big circles with black dots) are formed by direct shedding of the plasma membrane and release
to the extracellular space. The right panel shows different possible routes for EV uptake. On one hand, EVs can establish specific binding with the plasma membrane
followed by direct fusion of EV and cell membrane inducing the release of the EV cargo into the cytoplasm of the target cell (1). Altogether, various EVs can also be
internalized by endocytosis, which once in the cytosol can either be directed to the lysosome for degradation or release their content to the cytosol by back-fusion of





their intracellular transcriptome, proteome and lipidome to
the extracellular space they reach, communicating their
‘status’ to other cells. EVs can be subdivided into three
main categories depending on their subcellular origin: exo-
somes, microvesicles and apoptotic bodies [9,10]. Exosomes
are the smallest of EVs, with a size ranging from 30–150 nm.
They are generated inside multivesicular bodies (MVBs)
and are released upon the fusion of the MVB with the
plasma membrane [11]. Microvesicles have been previously
referred to as ectosomes or oncosomes and range from 100
to 1000 nm. They are formed, matured and released by shed-
ding from the plasma membrane of the cell (figure 1; left
panel). Both microvesicles and exosomes comprise the
accumulation of intracytosolic components although the
protein and lipid composition between both EV subtypes dif-
fers [8,12]. Apoptotic bodies are the largest of all EVs (up to
5000 nm) and are released as membrane blebs of cells under-
going apoptosis. Throughout this review we will focus
exclusively on the role of exosomes and microvesicles in the
tumour microenvironment using the generic name of EVs,
without specifying which type of EVs the original research
studies are referring to.
(a) Extracellular vesicle function in the extracellular
space: uptake mechanisms
Upon the release by the parental cell, EVs can act either
locally or systemically on neighbouring cells (figure 1). In
fact, EVs can travel through blood and/or lymphoid nodes
from other tissues [13]. It is therefore not surprising that
EVs have been found in a number of biological fluidsincluding plasma, urine, breast milk, semen, cerebrospinal
fluid and saliva [8].
The exact EV uptake mechanisms for recipient cells are
not completely understood but different groups have pro-
vided evidence for EV cargo uptake by either: (i) direct EV
fusion at the plasma membrane, releasing the EV cytosol con-
tent into the cytoplasmic compartment of the target cells; or
(ii) by uptake through endocytosis followed by back-fusion
of the EV with the endosomal membrane releasing their con-
tents to the cytoplasm of the recipient cell (figure 1) [8]. In
fact, in 2007, Valadi et al. demonstrated that mRNA and
microRNA (miR) could be transferred via EVs from mouse
to human mast cells. They also showed that the RNA content
was functional as they found mouse proteins in the human
recipient cells [14]. The delivery of EVs derived from dendri-
tic cells (DC) loaded with an siRNA targeting GAPDH
showed a reduction in the expression levels of GAPDH in
neurons, microglia, oligodendrocytes demonstrated that the
siRNA was effectively transferred and functional [15]. Fur-
thermore, performing membrane fusion assays using EVs
loaded with luciferin substrate to treat luciferase-expressing
cells resulted in production of bioluminescence in the recipi-
ent cells [16]. It was also demonstrated that heparan sulphate
proteoglycans (HSPGs) function as essential receptors for the
endocytosis of cancer-derived EV [17] and recently, Neuropi-
lin-1 has been confirmed as a receptor for extracellular
miRNA and AGO2/miRNA complexes internalization in
recipient cells [18]. Altogether, these and many other studies
have shown that EVs can be effectively taken up by recipient
cells, although it is possible that the EV uptake mechanism is
cell-type– and context-dependent.
rstb.royalsocietypublishing.org
3EVs do seem to have some characteristics that favour
cell-specific uptake. For example, EVs derived from platelets
preferentially transferred tissue factor (TF) to macrophages
but not neutrophils [8], while EVs derived from different
tumours are taken up by cells within their preferential meta-
static site and depend on their preferred integrin expressed
[19,20] and exosomes derived from K562 or MT4 cells were
internalized more efficiently by phagocytes than by non-
phagocytic cells [21]. These heterogeneous responses are
not surprising though the particular proteins involved from
both EVs and recipient cells remain to be elucidated.Phil.Trans.R.Soc.B
373:201604883. Role for extracellular vesicles in cancer
The complexity of tumours is becoming increasingly recog-
nized with the view of tumours formed exclusively from
cancer cells now being obsolete. In fact, a variety of cell
types such as fibroblasts, lymphocytes, inflammatory cells,
epithelial cells, endothelial cells and mesenchymal stem
cells can be found within the tumour microenvironment
[22]. Although for years the main mediator for the tumour
intercellular communication was attributed to secreted pro-
teins like growth factors, cytokines and chemokines recent
advances in cancer biology show that EVs play a key role
in this communication process [8]. Therefore, the need for a
coordinated multistep programme and a multifaceted signal-
ling network between all the different cell types is necessary
for the success of tumour development [22].
(a) Extracellular vesicles released by tumour cells can
both suppress and activate the immune system
EVs have been shown to be involved in the regulation of an
immune response and therefore much attention has been
brought in the cancer field to the interplay between tumour
EVs and the immune system regulation [23]. Importantly,
it seems that the initial local interaction between tumour
cells and the innate immune response might be critical in
influencing tumour fate [19].
Tumour-derived EVs are a reflection of the protein
composition of the parental cell. Therefore, EVs can con-
tain tumour-specific antigens such as carcinoembryonic
antigen (CEA) and mesothelin [24]. As a consequence,
tumour-specific antigens can induce the maturation of anti-
gen-presenting cells (APC), stimulating cytotoxic CD8þ T
and natural killer (NK) cells, eventually eliminating cancer
cells [25,26]. This anti-tumour response is in line with pre-
vious reports, where EVs derived from DC cells functionally
express MHC Class I and II molecules, inducing anti-tumour
responses dependent on CD8þ T lymphocyte activation
[7,27]. Interestingly, Headly et al. have shown that circulating
tumour cells from the lung release EVs that migrate along
the lung vasculature and are subsequently taken up by
myeloid cells. As a consequence, this activates DC cells that
initiate an anti-tumour response [28]. Another recent study
has also shown that the loss of the Hippo pathway kinases
large tumour suppressor 1 and 2 (LATS1/2) in tumour
cells inhibits tumour growth by nucleic-acid-rich-EVs, which
induce a type I interferon response (IFN) via the Toll-like
receptors-MYD88/TRIF pathway [29].
Although the activation of the immune system can
initially reduce tumour growth, cancer cells generally havedefence mechanisms to evade immune surveillance. Pucci
et al. have found that tumour-derived EVs preferentially
bind subcapsular sinus of lymph nodes, where a specialized
population of macrophages (CD169þ) block the dissemination
of cancer EVs. Interestingly, this barrier is altered during
cancer allowing the tumour-derived EVs to travel along the
lymph nodes and activate B lymphocytes promoting tumour
growth [30].
In fact, tumour-derived EVs create an immunosuppres-
sive niche that protects the tumour from the immune
system [31,32]. For example, EVs derived from breast cancer
cells were shown to activate tumour-activated macrophages
(TAMs), inducing the secretion of IL-6, tumour necrosis
factor alpha (TNFa), granulocyte-colony stimulating factor
(G-CSF) and CCL2 by NK-kB activation and promoting
vascularization and angiogenesis [33]. Furthermore, TGFb
was found to be essential for the recruitment of tumour-
associated neutrophils to the tumour [34], and breast
cancer–derived EVs can immobilize neutrophils in the
tumour promoting cancer progression [35]. In addition, EVs
derived from serum of patients with cancer have been
shown to express FasL and TRAIL as transmembrane pro-
teins, activating programmed cell death or apoptosis in
cytotoxic CD8þ T cells [31]. The TNF superfamily member,
CD95 L, is also found in tumour EVs and mediates
immune evasion, and the presence of CD11b in tumour
EVs suppresses antigen-specific responses via an MHC
class II–dependent mechanism [24]. The existence of this
immunosuppressive niche is reinforced by the activation of
DC by tumour-derived EVs [24,32], and by favouring the
generation of myeloid-derived suppressor cells (MDSCs),
that contain prostaglandin E2 (PGE2), transforming growth
factor-b (TGFb) and heat shock protein 72 (HSP72) in their
secreted vesicles [24]. All these studies show that EVs derived
from tumour cells present a wide range of antigens capable of
evading immune surveillance.
(b) Tumour-derived extracellular vesicles influence the
transition to metastasis
Apart from evading immune surveillance, cancer cells need
alternative pathways in order to successfully grow and colonize
foreign tissues. In this section, we will explain how tumour-
derived EVs contribute to the step necessary to transition to
metastasis such as inducing changes in the tumour stroma, pro-
moting angiogenesis and favouring epithelial–mesenchymal
transition (EMT).
For the tumour to continue progressing, a complex stro-
mal support is needed [22]. Cancer-stroma is mainly
composed of the cancer-associated fibroblasts (CAFs) sub-
type myofibroblasts, which release enzyme-degrading
proteases or metalloproteases (MMPs) that contribute to the
formation of desmoplastic stroma, a feature of advanced car-
cinomas. EVs containing TGFb have been shown to drive
tissue-resident fibroblasts into myofibroblasts demonstrated
by the expression of a-smooth muscle actin (a-SMA) [36,37].
Furthermore, CAFs can secrete EVs inducing protrusive
activity and mobility in breast cancer cells by a Wnt-driven
planar cell polarity [38] and transfer radiation and che-
motherapy resistance in the form of EV messaging [39]. In
addition, a recent paper has shown that melanoma cells
release EVs carrying miR-211, inducing the activation of




























Figure 2. Tumour-derived EVs influence the microenvironment to promote tumour progression. The tumour microenvironment is comprised of a variety of cell types,
which interact with each other via different signalling mechanisms. Tumour-derived EVs induce the activation of tissue-resident fibroblasts into myofibroblasts,
cancer-associated fibroblasts (CAFs), which in turn modify the ECM favouring cancer cell growth and the recruitment of immune cells. In fact, EVs derived
from cancer cells can exert both anti-tumour and pro-tumour activities on different cells of the immune system, which as a consequence secrete their own
EVs altering the behaviour of cancer cells. Furthermore, tumour-derived EVs contribute to numerous steps required for the progression from a primary tumour
to the final stages of metastasis, such as stimulating epithelial to mesenchymal transition (EMT), the formation of new blood vessels (angiogenesis), vascular





between CAFs and cancer cells via EVs is an important inter-
cellular communication mechanism that induces changes in
the tumour microenvironment (figure 2).
EVs derived from several human cancer cells have been
shown to induce angiogenesis. One particular example is
EVs derived from renal cancer cells that promote angiogen-
esis in the lung [41]. In addition, epidermal growth factor
receptor, EGFR-enriched EVs produced by cancer cells are
uptaken by endothelial cells, inducing vascular endothelial
growth factor (VEGF) and VEGF receptor 2 expression [42],
while TF-containing EVs upregulate angiogenesis [43]. Fur-
thermore, the transfer of the microRNA miR-150 from EVs
to TAM leads to a proangiogenic environment through the
secretion of VEGF [44].
Tumour-derived EVs also can activate EMT transition in
epithelial cells triggering their loss of cell adhesion. The
loss of adhesion alters the encapsulated structure of the pri-
mary tumour facilitating the release of tumour cells to
distant sites to induce metastasis. In fact, a number of studies
have observed that EVs derived from Madine-Darby canine
kidney epithelial cells and the breast metastatic cell line
MDA-MB-231 can induce EMT in recipient cells [45,46].
Overall, all these series of events allow the tumour to
progress and metastasize.(c) Extracellular vesicles play an important role in the
formation of secondary tumours and metastasis
As tumours evolve, their intercellular communication
becomes distorted, with EVs derived from tumour cells
affecting all hallmarks of cancer [22].
In 1889 Stephen Paget observed that different tumour
types have preferential metastatic sites [47], while Ernest
Fuchs perceived that those sites must be predisposed for
allowing ‘foreign cell’ growth. In fact, the role for EVs in
creating an ideal premetastatic niche is becoming increasingly
recognized. The contribution to soluble factors and EVs from
a subtype of pancreatic cancer cells to predispose thelymphoid node and lung was first made by Jung et al. [48].
However, many other studies followed this observation.
The blood vessels produced within tumours are typically
aberrant allowing vascular leakiness and abnormal endo-
thelial cells morphology [22]. Tumour-derived EVs also
contribute to the induction of vascular leakiness, an
additional factor that contributes to EV-promoted metastasis.
Melanoma-derived EVs induce the upregulation of S100 pro-
teins and TNFa, causing vascular leakiness, inflammation
and bone marrow progenitor recruitment [49]. Similarly,
breast-derived EVs also promote vascular leakiness by acti-
vating Src kinase signalling pathway [50] and through the
release of exosomal miR-105, which targets the mRNA encod-
ing the tight junction protein ZO-1 in endothelial cells [51].
Several groups have found that upregulation of S100 and
MMP proteins mediated by tumour EVs creates a premeta-
static niche, either by enhancing vascular leakiness [49] or
by TLR3 activation [52]. In fact, MMPs present in tumour-
derived EVs can influence the ECM, inducing morphological
changes ultimately leading to metastasis [38,53]. Interest-
ingly, a recent study has found a specific pattern for
integrin expression in tumour-derived EVs, which directs
EVs to specific metastatic sites via S100 upregulation. Thus,
EVs containing integrins a6b4 and a6b1 have been associ-
ated with lung metastasis, while avb5-expressing EVs are
linked to liver metastasis [50]. Another study found that fibro-
nectin (FN)-integrin a5b1 EVs derived from fibrosarcoma
promoted cell migration in vitro and in vivo [54]. In fact, integ-
rin signalling via focal adhesion kinase (FAK) is considered a
possible mechanism of EV signalling in cancer [55].
In recent years, the transfer of RNA within tumour EVs
has generated a great interest in the cancer community.
A study by the Lötvall group showed that mast cell–derived
EVs contain and transfer miR and mRNA to recipient cells,
therefore regulating gene expression [14]. Likewise, several
miR targeting the tumour suppressor gene PTEN have been
found in astrocyte-derived EVs, enhancing the growth of
brain metastatic cells [56]. Interestingly, exosome cargo can




5that breast-derived mir-122 can be transferred to stromal
fibroblasts and prevent glucose uptake by downregulating
pyruvate kinase [57]. However, further thorough investi-
gation is needed to conclusively confirm EV-dependent
transport and expression of miR.
Once the premetastatic niche is conditioned by tumour
EVs, this influences the recruitment of additional cells to pro-
mote the growth of secondary tumours. Both melanoma and
pancreatic tumour EVs induce the recruitment of bone
marrow-derived cells (BMDC) [49,58]. In particular, EVs
from pancreatic cancer cells activate resident macrophages
in the liver (Kupffer cells), which release TGFb. TGFb in
turn activates hepatic stellate cells (HSCs) that induce ECM
remodelling prompting the recruitment of BMDC [58].
It seems that the receptor tyrosine kinase receptor Met
plays a key role in metastatic EV-mediated preconditioning.
Met can be found in tumour EVs and can be transferred
to recipient cells, which in turn promote tumorigenesis
[49,59,60]. However, cancer cells also release EVs containing
other oncogenic proteins. The oncogene KIT was found in
EVs derived from gastrointestinal tumours [61], while a trun-
cated oncogenic form of the epidermal growth factor receptor
(EGFRvIII) can be uptaken by cells negative for the receptor
via EV transfer [62]. Altogether, these studies suggest that
the presence of the oncogene Met in EVs is not the only
mechanism involved in promoting metastasis.4. Future directions
Tumour-derived EVs prepare the premetastatic niche for
metastasis. To deal with this issue, a recent study created
an artificial premetastatic niche by embedding tumour-
derived EVs in a 3D scaffold device, which they calledM-Trap. By implanting M-Trap in an animal model, they
could observe a reduction in the metastatic potential of ovar-
ian tumour cells and an increase in the survival rate of the
mice [63]. Altogether this technique could potentially present
a promising approach to deal with cancer metastasis,
although a more detailed investigation into different types
of cancer and the precise mechanism implicated would
be needed.
Another question that remains to be answered is: Why not
inhibit EV biogenesis if it is so detrimental in cancer? Several
studies have tried this approach with more or less success.
Interference with some Ras-related RAB proteins, which are
essential for EV biogenesis, has been shown to reduce
migration, growth and metastasis [1]. However, although a
reduction in the metastatic potential induced by injecting
EVs from RAB-depleted cells was observed, metastasis was
not completely abolished, suggesting either additional mech-
anisms unrelated to EV biogenesis are implicated or that
affecting EV biogenesis influences other cellular signalling
pathways. This further highlights the existing complexity
of the different EV subtypes and their functionality,
which is an area of enormous interest in the field. In fact,
further basic and translational research on this topic is
likely to pay dividends in terms of regaining control of
our understanding of the cancer microenvironment and
metastatic dissemination.Data accessibility. This article has no additional data.
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